Praxis posts Q1 net loss of $69.3M; cash $472M, runway into 2028

Praxis Precision Medicines, Inc.

2025-Q1 EPS reported -$3.29

Net loss $69.3M for Q1 2025 vs $39.6M YoY; R&D spend $60.8M (up 125% YoY).
Cash & investments $472M as of March 31, 2025; no revenue recognized.
Essential3 essential tremor trial continues after futility interim; topline Q3 2025.
Vormatrigine RADIANT topline mid-2025, POWER1 H2 2025; EMERALD & EMBRAVE3 studies to start mid-2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.